Prazer Therapeutics
Manufacturing · South Korea · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1103 d Beobwon-ro 9-gil Dept 26, Songpa-...Phone Number
+82 262171020Website
www.prazertx.comRevenue
$5.9 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Prazer Therapeutics
Prazer Therapeutics is a biotechnology company pioneering innovative therapeutics for various intractable diseases using rational drug design and next-generation targeted protein degradation (TPD) platform called SPiDEM. Our SPiDEM-based drug candidates for neurodegenerative diseases, cancers and inflammatory diseases have demonstrated superior pharmacokinetics and efficacy as well as reduced drug resistance compared to currently available TPD technologies. Our pipeline also encompasses anti-viral therapeutics to treat chronic hepatitis B (CHB) caused by hepatitis B virus (HBV) as well as acute lung inflammation caused by coronaviruses, influenza viruses and respiratory syncytial virus (RSV).Explore more
Prazer Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Prazer Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Prazer Therapeutics recently announced quarterly report
Prazer Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Prazer Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Check if Prazer Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Check out if Prazer Therapeutics is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Prazer Therapeutics
Click to see if Prazer Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Prazer Therapeutics has new funding data
Recommended Actions
Find VP level buyers at Prazer Therapeutics
Find 2 more new buyers
Company Profile Activity
Activity Insights
Prazer Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Prazer Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Prazer Therapeutics.
Prazer Therapeutics financials insights
Gather financial insights about Prazer Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Series B
$19.6M
Prazer Therapeutics Tech Stack
Most Recent Scoops
Event
Product Marketing, Events, Learning & Development, Software, Bioengineering, Pharmaceuticals, Public Health, Field /Outside Sales, Field Marketing, Healthcare Technology, Patient Experience
Funding
Funding
Event
Events
Event
Prazer Therapeutics News & Media
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Prazer Therapeutics
Sign Up For FreeTo access detailed company insights
Prazer Therapeutics is a biotechnology company pioneering innovative therapeutics for various intractable diseases using rational drug design and next-generation targeted protein degradation (TPD) platform called SPiDEM. Our SPiDEM-based drug candidates for neurodegenerative diseases, cancers and inflammatory diseases have demonstrated superior pha... Read More
